Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
Edgewise reported second-quarter 2026 financial results, highlighted by the July closure of its sevasemten and muscular dystrophy business sale to Servier for $1.55 billion in upfront cash. The transaction strengthens the balance sheet significantly, providing a pro forma cash position of approximately $2.01 billion to fund the advancement of its cardiovascular pipeline.
Key figures
- Deal Value Usd
- 2650000000
- Net loss
- 57300000
- Ga expenses
- 14400000
- Rd expenses
- 47500000
- Upfront proceeds
- 1550000000
- Cash position june 30
- 460700000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.